bluebird bio Inc reports results for the quarter ended December 31 - Earnings Summary

bluebird bio

28/03/2025 06:09

bluebird bio Inc BLUE.OQ reported a quarterly adjusted loss of $2.95​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-15.60.  The mean expectation of seven analysts for the quarter was for a loss of $5.98 per share. Wall Street expected results to range from $-8.25 to $-3.65 per share.

Revenue rose 391.7% to $38.52 million from a year ago; analysts expected $27.08 million.

bluebird bio Inc's reported EPS for the quarter was a loss of $2.95​.

The company reported a quarterly loss of $28.64 million.

bluebird bio Inc shares had fallen by 54.6% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 0.2% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "hold"

Wall Street's median 12-month price target for bluebird bio Inc is $8.00

This summary was machine generated from LSEG data March 28 at 06:09 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-5.98
-2.95
Beat
Sep. 30 2024
-7.29
-6.20
Beat
Jun. 30 2024
-8.33
-8.40
Missed
Mar. 31 2024
-8.81
-7.20
Beat